Dyspareunia and Lubrication in Premature Ovarian Failure Using Hormonal Therapy and Vaginal Health
Overview
Affiliations
Objective: To evaluate vaginal microbiological and functional aspects in women with and without premature ovarian failure (POF) and the relationship with sexual function.
Methods: A cross-sectional study of 36 women with POF under hormonal therapy who were age-matched with 36 women with normal gonadal function. The vaginal tropism was assessed through hormonal vaginal cytology, vaginal pH and vaginal health index (VHI). Vaginal flora were assessed by the amine test, bacterioscopy and culture for fungi. Sexual function was evaluated through the questionnaire Female Sexual Function Index (FSFI).
Results: Women in both groups were of similar age and showed similar marital status. The two groups presented vaginal tropic scores according to the VHI but the tropism was worse among women in the POF group. No difference was observed with respect to hormonal cytology and pH. Vaginal flora was similar in both groups. Women with POF showed worse sexual performance with more pain and poorer lubrication than women in the control group. The VHI, the only parameter evaluated showing statistical difference between the groups, did not correlate with the domains of pain and lubrication in the FSFI questionnaire.
Conclusion: These findings suggest that the use of systemic estrogen among women with POF is not enough to improve complaints of lubrication and pain despite conferring similar tropism and vaginal flora. Other therapeutic options need to be evaluated.
Bai T, Deng X, Bi J, Ni L, Li Z, Zhuo X Front Med (Lausanne). 2024; 11:1471243.
PMID: 39655237 PMC: 11627218. DOI: 10.3389/fmed.2024.1471243.
Primary ovarian insufficiency: update on clinical and genetic findings.
Federici S, Rossetti R, Moleri S, Munari E, Frixou M, Bonomi M Front Endocrinol (Lausanne). 2024; 15:1464803.
PMID: 39391877 PMC: 11466302. DOI: 10.3389/fendo.2024.1464803.
The impact of premature ovarian insufficiency on sexual function; which domain is mostly disrupted?.
Farahmand M, Ramezani Tehrani F Int J Impot Res. 2024; 36(8):873-878.
PMID: 38418866 DOI: 10.1038/s41443-024-00851-4.
Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?.
Loizzi V, Dellino M, Cerbone M, Arezzo F, Chiariello G, Lepera A Hormones (Athens). 2023; 22(1):19-23.
PMID: 36637775 DOI: 10.1007/s42000-022-00427-1.
Changes in the vaginal microbiota associated with primary ovarian failure.
Wang J, Xu J, Han Q, Chu W, Lu G, Chan W BMC Microbiol. 2020; 20(1):230.
PMID: 32727366 PMC: 7392721. DOI: 10.1186/s12866-020-01918-0.